Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck

CONCLUSIONS: (Neo)adjuvant N+L was well tolerated with a 43% pathologic response rate. We observed favorable DFS and excellent 2-year OS among high-risk, previously treated patients exhibiting a pathologic response. Further evaluation of this strategy is warranted.PMID:34667025 | DOI:10.1158/1078-0432.CCR-21-2635

Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Glenn J Hanna Anne ONeill Kee-Young Shin Kristine Wong Vickie Y Jo Charles T Quinn Jennifer M Cutler Michelle Flynn Patrick H Lizotte Donald J Annino Laura A Goguen Jason I Kass Eleni M Rettig Rosh K V Sethi Jochen H Lorch Jonathan D Schoenfeld Danielle N Source Type: research